Macrogen Selects GenoLogics’ Clarity LIMS to Strengthen X-Genome and Clinical Sequencing Services
- Strengthening the Support for researchers and Clinical Customers
- Reinforcing the Market Leadership through the X-Genome and Clinical Sequencing Service
Victoria, Canada and Seoul, South Korea, October 20, 2014 (BusinessWire) - The personalized medicine biotechnology company Macrogen (www.macrogen.com) has announced it introduced the Clarity Laboratory Information Management System (LIMS) from GenoLogics Life Sciences Software (www.genologics.com), a leading provider of LIMS specifically designed for omics labs to support its whole-genome sequencing and clinical sequencing services.
d in Canada, GenoLogics develops and supplies the LIMS to organizations that conduct research d on various genome analysis technologies.
With the introduction of GenoLogics’ Clarity LIMS, Macrogen plans to strengthen its support for researchers and clinical customers by automating the analysis of whole-genome sequencing and clinical sequencing services, and systematically managing the strict requirements of clinical environments.
In January 2014, Macrogen became an early adopter of Illumina’s HiSeq X™ Ten platform to pioneer new diagnostic and genomics services and strengthen the foundation for personalized medicine. The company also launched the X-Genome (Xpressway to Genome) service for researchers who conducts the large-scale whole-human genome sequencing d studies. Moreover, Macrogen has established a U.S. subsidiary, Macrogen Clinical Laboratory, Inc. (MCL), which has set up the CLIA (Clinical Laboratory Improvement Amendments)-certified clinical laboratory last year in order to provide the clinical sequencing d healthcare services for physicians and patients. As such, Macrogen plans to introduce the Clarity LIMS to its MCL subsidiary first.
"The US subsidiary MCL selected GenoLogics’ Clarity LIMS after recognizing that it is the optimum means of providing the whole-genome sequencing service through close cooperation with the Korean Headquarter while satisfying the strict requirements of CLIA regarding the clinical sequencing service," said Kim Hyung-tae, CEO of Macrogen. "Through the X-Genome service d on the HiSeq X Ten system for whole-human genome sequencing research, Macrogen is strengthening its competitive edge in the existing research market and establishing its leading position in the clinical sequencing service market."
"GenoLogics’ Clarity LIMS makes it possible to improve the overall efficiency and results of genome research," states Michael Ball, CEO of GenoLogics. "We are pleased to be in a position to supply the system to Macrogen through automating the analysis of X-Genome and clinical sequencing services."